Orforglipron

Foundayo, oral GLP-1Not a peptide · small-molecule pillMetabolic/Weight

Evidence grade

AFDA-approved Rx (labeled use)

Cardiovascular · 0–5 · separate axis

Read first · not dosing instructions

Educational and research reference only. Not medical advice, not a recommendation, and not dosing instructions for any person. Figures are reported from the cited source and may be wrong or out of date. Research peptides are not approved for human use. Adults 18+. Consult a licensed physician before any decision about your health.

PurposeMetabolic / Weight loss

MechanismNon-peptide small-molecule GLP-1 receptor agonist taken orally, with no food, water or timing restriction — the property that separates it from oral semaglutide.

EffectsAppetite reduction and weight loss from a daily tablet. In ATTAIN-1, participants on the highest dose who stayed on treatment lost about 12.4% of body weight against 0.9% on placebo.

DosingOral tablet once daily: 0.8 mg for at least 30 days, then 2.5 mg, then 5.5 mg; optionally 9 mg, 14.5 mg and 17.2 mg, each step after at least 30 days, by response and tolerability. Maximum 17.2 mg daily, or 9 mg daily with a strong CYP3A4 inhibitor. Approved by the FDA in April 2026 for chronic weight management in adults with obesity, or overweight with a weight-related condition.

Bottom lineThe second oral GLP-1 to reach market and the first with no food or water restriction. Approved, with real trial data behind it.

Protocols · as published1 sourced

FDA labelFoundayo (FDA approval 2026-04-01)

RouteOral tablet

FrequencyOnce daily, with or without food

Starting0.8 mg once daily for at least 30 days

Escalation2.5 mg for at least 30 days, then 5.5 mg; then optionally 9 mg, 14.5 mg and 17.2 mg, each after at least 30 days, based on treatment response and tolerability

Target5.5, 9 or 17.2 mg once daily (the randomised maintenance doses)

Maximum17.2 mg once daily; 9 mg once daily with a strong CYP3A4 inhibitor

If 7 or more consecutive doses are missed, restart escalation at a lower dose. With oral contraceptives, add a barrier method for 30 days after starting and after each escalation.

SourceFoundayo label (FDA) ↗

Batches on filenone

No tested batches on file.

Read with

The library records no pairings for this entry.

Cautions & interactions

Boxed warning for thyroid C-cell tumours. Nausea, diarrhoea, constipation and indigestion are common, worst on starting or escalating, and settle over time. Pancreatitis and hypoglycaemia are less common but need prompt attention.

As a GLP-1 agonist, caution with insulin and sulfonylureas for hypoglycaemia risk. Delayed gastric emptying can affect absorption of oral medications.

CV 3 of 5 — Shares the class metabolic profile — weight, glucose and blood pressure improvement. No dedicated cardiovascular outcomes trial has read out, so the outcome data behind semaglutide does not transfer to it yet.